title: Abacavir/lamivudine/zidovudine continues to be a valid and useful antiretroviral regimen.
authors.affiliation: HIV, Infectious Disease Medicine Development Center, GlaxoSmithKline, Five Moore Dr, Research Triangle Park, NC 27709-3398, USA. mark.s.shaefer@gsk.com
authors.forename: Mark S
authors.initials: MS
authors.lastname: Shaefer
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015224:Dideoxynucleosides / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D015215:Zidovudine / Q000627:therapeutic use*; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D019259:Lamivudine; D015215:Zidovudine; D000099227:Abacavir